M. Brill

发表

Semiphysiologically based pharmacokinetic model for midazolam and CYP3A mediated metabolite 1‐OH‐midazolam in morbidly obese and weight loss surgery patients

M. Danhof, A. Rostami-Hodjegan, B. van Ramshorst, 2015, CPT: pharmacometrics & systems pharmacology.

Relationship between the degree of coronary artery disease and of left ventricular function and the duration of the QT-interval in ECG.

W. Kübler, B. Krämer, M. Brill, 1986, European heart journal.

Population Pharmacokinetic Model Characterizing 24-Hour Variation in the Pharmacokinetics of Oral and Intravenous Midazolam in Healthy Volunteers

J. den Hartigh, F. van Oosterhout, J. Burggraaf, 2015, CPT: pharmacometrics & systems pharmacology.